- Patients already on therapy with Acupil® for a minimum period of 4 weeks, Evidence of
a personally signed and dated informed consent document
- Patients having a Week 0 visit blood pressure reading of more than 180/110 mm of Hg
will not be eligible to participate in the study.
- Women of child bearing age, not willing to use contraceptives, will not be eligible
for the study
- Women using oral contraceptives will also not be included in the study
- Patients who have received any drug other than Acupil® as the first prescribed
antihypertensive would not be eligible for enrollment into the trial
- Patients having any complication at Week 0 visit which would require more thorough
investigations or who required more than one anti-hypertensive drug at the time of
initiation of their therapy will not be included in the study
- Patients having any contraindications as per the LPD of Acupil®